Cellares teams up with Bristol Myers Squibb to explore automated CAR-T cell therapy manufacturing

Less than a week after announcing that it has secured $255 million in Series C funding, South San Francisco-based startup Cellares has revealed that Bristol Myers Squibb has joined its Technology Adoption Partnership (TAP) program. To date, the company has raised more than $355 million in total financing.

As part of the TAP program, Bristol Myers Squibb plans on conducting a proof-of-concept transfer of a CAR-T cell therapy process onto the Cell Shuttle, which the company has called a “factory in a box.”

Cellares plans to use the funding to launch what it dubs the world’s first commercial-scale Integrated Development and Manufacturing Organization (IDMO) smart factory. Koch Disruptive Technologies led the investment round, which included participation from Bristol Myers Squibb, DFJ Growth, Willett Advisors, Eclipse, Decheng Capital and 8VC.

When asked how Cellares managed to receive a large funding round in a difficult financial climate, Gerlinghausen sa…

Read more
  • 0

Discover new levels of efficiency in pharma manufacturing with advanced analytics

[max_776/Adobe Stock]

Digitalization empowers pharmaceutical companies to bring therapies to patients faster by using advanced analytics strategies to profitably optimize manufacturing operations.

In the pharmaceutical industry, operational issues from efficiency losses to failed batches can delay delivery of potentially lifesaving therapies to patients. For this and other reasons, pharmaceutical organizations require resources dedicated to batch prediction, planning and rapid issue resolution throughout the entirety of a drug’s lifecycle. Because the field is both highly regulated and consequential, decisions must be data-based to ensure compliance and product integrity.

Adding to the challenge, patient populations are ever-evolving and conditions in the supply chain are variable. At the same time, there is growing pressure to lower the cost of bringing drugs to market, without compromising safety and…

Read more
  • 0